Reviewing Vericel (VCEL) & Aptose Biosciences (APTO)

Vericel (NASDAQ:VCEL) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Profitability

This table compares Vericel and Aptose Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vericel -23.35% -37.86% -21.19%
Aptose Biosciences N/A -179.38% -156.00%

Risk and Volatility

Vericel has a beta of 3, meaning that its stock price is 200% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Vericel and Aptose Biosciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel 0 0 5 0 3.00
Aptose Biosciences 0 0 3 0 3.00

Vericel currently has a consensus price target of $15.00, indicating a potential upside of 34.53%. Aptose Biosciences has a consensus price target of $7.33, indicating a potential upside of 237.94%. Given Aptose Biosciences’ higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Vericel.

Institutional & Insider Ownership

76.5% of Vericel shares are owned by institutional investors. Comparatively, 2.4% of Aptose Biosciences shares are owned by institutional investors. 4.7% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Vericel and Aptose Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vericel $63.92 million 7.45 -$17.28 million ($0.50) -22.30
Aptose Biosciences N/A N/A -$11.66 million ($0.52) -4.17

Aptose Biosciences has lower revenue, but higher earnings than Vericel. Vericel is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Aptose Biosciences on 8 of the 12 factors compared between the two stocks.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Aptose Biosciences Company Profile

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply